



شبكة المعلومات الجامعية  
التوثيق الإلكتروني والميكروفيلم

# بسم الله الرحمن الرحيم



**HANAA ALY**



شبكة المعلومات الجامعية  
التوثيق الإلكتروني والميكروفيلم



## شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



**HANAA ALY**



شبكة المعلومات الجامعية  
التوثيق الإلكتروني والميكروفيلم

# جامعة عين شمس التوثيق الإلكتروني والميكروفيلم

## قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها  
علي هذه الأقراص المدمجة قد أعدت دون أية تغييرات



## يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



**HANAA ALY**



## **Vesicular systems for the topical delivery of nobiletin**

A Thesis submitted

By

**Mahitab Mohamed Kamel Bayoumi**

Bachelor degree of pharmaceutical sciences and drug design, 2014,  
Ain Shams University

Teaching Assistant, Department of Pharmaceutics and Pharmaceutical technology

Faculty of Pharmacy, The British University in Egypt

For the partial fulfillment of Master Degree in Pharmaceutical Sciences  
(Pharmaceutics)

*Under Supervision of*

***Prof. Dr. Omaima A. Sammour***

Professor of Pharmaceutics and Industrial Pharmacy  
Faculty of Pharmacy- Ain Shams University.

***Assoc. prof. Maha Nasr Sayed***

Associate Professor of Pharmaceutics and Industrial Pharmacy  
Faculty of Pharmacy - Ain Shams University.

***Assoc. prof. Mona Gamal Arafa***

Associate Professor of Pharmaceutics and Pharmaceutical technology  
Faculty of pharmacy- The British University in Egypt.

Associate consultant of Pharmaceutics and pharmaceutical technology  
Mansura University Hospitals- Mansura University.

**2020**

## **Acknowledgements**

*First of all, “All the praises and thanks be to ALLAH, who has guided us to this, and never could we have found guidance, were it not that ALLAH had guided us”.*

*I would like to express my sincere gratitude to **Professor Dr. Omaïma Sammour**, professor of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, for being a great supervisor, believing in me and teaching me how to go after my ambitions under any circumstances. Her great knowledge and valuable guidance helped me a lot to improve this work. She taught me that accuracy and honesty are the most important assets of a researcher. I will forever be grateful for being one of her undergraduate and postgraduate students.*

*I would like to offer my deep appreciation and gratitude to **Assoc. prof. Maha Nasr Sayed**, Associate Professor of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University for being an extraordinary teacher and scientist who never failed to guide me at all times. Her knowledge, dedication, patience and generous contribution to every step and each part of this thesis makes her a true inspiration. Her precious comments*

*and constructive criticism guided me to improve this work way beyond my expectations. All my success and knowledge in this field since I were an undergraduate student I owe to her.*

*I would deeply like to thank **Assoc. prof. Mona Gamal Arafa**, Associate Professor of Pharmaceutics and Pharmaceutical technology, Faculty of pharmacy, the British University in Egypt for her genuine support from the time I started my career. Her loving, kind soul as well as her success and devotion for her work showed me the way to accomplishment. My work wouldn't have been that valuable without her contribution all through the thesis. She never failed to support and encourage me in every possible way. I am blessed to work under her supervision from day one of my career.*

*I would especially like to thank **Professor Dr. Mohey El Mazar**, the Dean of faculty of pharmacy, the British University in Egypt, for all the encouragement, guidance and support he gave me. He taught us that modesty, dedication and hard work always pays off. I will forever be grateful for the chance to work with him.*

*I would like to offer special thanks to our **HOD Professor Dr. Dalia Abd el Rahman** for being that supportive and*

*considerate since I started working in the department. She motivated me through the toughest times. I will forever be thankful for her advice and help.*

*I also like to thank all the members of the department of pharmaceuticals and pharmaceutical technology and all my colleagues for their support and help. I will keep their kindness always in my heart.*

*I would like to show my appreciation to all my friends, for giving me the best suggestions and always offering help and support. Sending my deep gratitude and love to my third sister, childhood friend and colleague **Salma Abdel aziz** for always holding my back and her endless help and support in all situations. She is definitely part of this success.*

*I would like to express my gratitude to my loving, caring husband, **Tariq Ashraf** for standing up for me and supporting me in all ways to complete this dream. He believed in me, I could have never completed this work without his support.*

*I would like to offer my special thanks to my sisters, **May and Mariam bayoumi** they are a precious gift from ALLAH, they helped me by all means at all times with love and patience. I always feel my success as one of their life goals. I will forever be grateful for having you as my sisters and backbone.*

*I would like to grip the opportunity and send my deep appreciation for my mother in law, Amany Sayed who helped and supported me through all times with love and patience.*

*I would love to send many thanks to my daughter, Houria, for her presence that taught me that I should do the best to make her proud.*

*Finally, I would like to thank Prof. Dr Sayed Abd El Reheem, Professor of Histology, faculty of medicine, Al- Azhar university as well as Prof. Dina Sabry, professor of biochemistry, Cairo university for their great effort and help in the in vivo part of our work.*

## **Dedication**

*I would love to gratefully dedicate this work to whom I did  
it for in the first place,  
my parents,*

*Mohamed Bayoumi and Mona Hussein*

*No words can ever be strong enough to express how I am grateful to have the most loving, caring, understanding, successful father and mother in the world. I give them all the credit to what I am today and will always do my best to make them proud till we meet again insha'allah.*

**List of contents**

| <b><i>Item</i></b>  | <b><i>Page</i></b> |
|---|--------------------|
| List of abbreviations   | <b><i>I</i></b>    |
| List of tables  | <b><i>IV</i></b>   |
| List of figures   | <b><i>VI</i></b>   |
| Abstract  | <b><i>X</i></b>    |
| General introduction  | <b><i>1</i></b>    |
| Scope of work   | <b><i>21</i></b>   |
| <b>Chapter I: Preparation and characterization of nobiletin vesicular systems</b>                       |                    |
| <b>Introduction</b>   | <b><i>23</i></b>   |
| <b>Materials</b>  | <b><i>33</i></b>   |
| <b>Equipment</b>  | <b><i>37</i></b>   |
| <b>Methodology</b>  |                    |
| 1- Spectrophotometric assay of nobiletin and construction of calibration curve                          | <b><i>35</i></b>   |
| 2- Preparation of nobiletin vesicular systems by the thin film hydration method                         | <b><i>35</i></b>   |
| 3- Determination of the particle size, polydispersity index and zeta potential of the prepared vesicles | <b><i>37</i></b>   |
| 4- Determination of nobiletin entrapment efficiency EE% in the prepared vesicles                        | <b><i>38</i></b>   |
| 5- Determination of viscosity   | <b><i>38</i></b>   |

|  |           |
|--|-----------|
| 6- Ultra performance liquid chromatography (UPLC) analysis of nobiletin for <i>ex vivo</i> deposition/ permeation study      | <b>38</b> |
| 7- <i>Ex vivo</i> deposition/permeation of nobiletin vesicular systems   | <b>39</b> |
| 8- Determination of the morphology of selected nobiletin vesicular formulations using transmission electron microscope (TEM) | <b>41</b> |
| 9- Studying the effect of storage on the physical stability of nobiletin selected vesicular systems                          | <b>41</b> |
| 10- Statistical analysis   | <b>41</b> |
| <b>Results and discussion</b>  |           |
| 1- Spectrophotometric assay of nobiletin and construction of calibration curve   | <b>42</b> |
| 2- Preparation of nobiletin vesicular systems  | <b>44</b> |
| 3- Determination of the particle size and polydispersity index (PDI) of the prepared vesicles                                | <b>46</b> |
| 3-1.Effect of the amount of transcutool on the particle size of nobiletin loaded PEVs and composite PEVs                     | <b>47</b> |
| 3-2.Effect of amount of tween 80 on the particle size of nobiletin transfersomes and composite transfersomes                 | <b>48</b> |
| 3-3.Effect of chitosan incorporation on the particle size of nobiletin vesicles  | <b>49</b> |
| 4- Determination of the charge of nobiletin vesicular systems  | <b>50</b> |
| 4.1.Effect of the amount of transcutool on the charge of nobiletin loaded PEVs and composite PEVs                            | <b>51</b> |
| 4-2.Effect of the amount of tween 80 on the charge of nobiletin loaded transfersomes and composite transfersomes             | <b>52</b> |
| 4-3.Effect of addition of chitosan on the charge of nobiletin loaded composite PEVs and composite transfersomes              | <b>52</b> |

|  |           |
|--|-----------|
| 5- Determination of the entrapment efficiency of nobiletin in vesicular systems              | <b>53</b> |
| 5-1. Effect of ceramide inclusion on the entrapment efficiency of nobiletin                  | <b>55</b> |
| 5-2. Effect of addition of chitosan on nobiletin encapsulation                               | <b>59</b> |
| 6- Characterization of the selected vesicles   | <b>61</b> |
| 6-1. Determination of viscosity  | <b>61</b> |
| 6-2. UPLC assay for nobiletin  | <b>63</b> |
| 6.2.1. Method Validation   | <b>63</b> |
| 6-3. <i>Ex vivo</i> deposition/permeation of nobiletin vesicles                              | <b>66</b> |
| 6-4. Transmission electron microscopy (TEM) examination                                      | <b>70</b> |
| 6-5. Effect of storage on the physical stability of the selected nobiletin vesicular systems | <b>73</b> |
| <b>Conclusions</b>   | <b>76</b> |
| <b>Chapter II: Cytotoxicity and <i>in-vivo</i> study of the selected nobiletin vesicles.</b> |           |
| <b>Introduction</b>  | <b>78</b> |
| <b>Materials</b>   | <b>82</b> |
| <b>Equipment</b>   | <b>84</b> |
| <b>Methodology</b>   |           |
| 1. <i>In-vitro</i> cytotoxicity assay of the selected nobiletin vesicles                     | <b>85</b> |
| 2. <i>In-vivo</i> assay of the anti-cancer activity of the selected nobiletin vesicles       | <b>87</b> |
| 2.1. Preparatory steps   | <b>87</b> |
| 2.2. Tumor induction   | <b>87</b> |

|  |            |
|--|------------|
| 2.3. Histological and immunohistochemistry studies                                     | <b>88</b>  |
| 2.4. Biochemical study of oxidative stress biomarkers and gene expression in skin      | <b>89</b>  |
| 2.4.1. Assay of glutathione activity   | <b>90</b>  |
| 2.4.2. Assay of lipid peroxidation   | <b>90</b>  |
| 2.4.3. Assay of superoxide dismutase activity  | <b>91</b>  |
| 2.4.4. Assay of catalase activity  | <b>92</b>  |
| 2.4.5. Assay of miRNAs   | <b>92</b>  |
| 3. Statistical analysis  | <b>92</b>  |
| <b>Results and Discussion</b>  |            |
| 1. <i>In-vitro</i> cytotoxicity assay of the selected nobiletin vesicles               | <b>94</b>  |
| 2. <i>In-vivo</i> assay of the anti-cancer activity of the selected nobiletin vesicles | <b>99</b>  |
| 3. Biochemical study   | <b>107</b> |
| <b>Conclusions</b>   | <b>113</b> |
| <b>Future perspectives</b>   | <b>115</b> |
| <b>Summary</b>   | <b>116</b> |
| <b>References</b>  | <b>120</b> |
| <b>Appendix I:</b> Research ethics committee approval for experimental studies         | <b>143</b> |
| <b>Appendix II:</b> Published Review article   | <b>145</b> |
| <b>Arabic summary</b>  | <b>\</b>   |

**List of abbreviations**

| <b>Abbreviation</b> | <b>Meaning</b>                    |
|---------------------|-----------------------------------|
| <b>5-FU</b>         | 5-Fluorouracil                    |
| <b>AC</b>           | Adnexal Carcinoma                 |
| <b>BCC</b>          | Basal Cell Carcinoma              |
| <b>CAT</b>          | Catalase                          |
| <b>COX-2</b>        | Cyclooxygenase2                   |
| <b>cP</b>           | Centipoise                        |
| <b>CS</b>           | Cutaneous Sarcoma                 |
| <b>Ct</b>           | Cycle Threshold                   |
| <b>CTLA4</b>        | T-Lymphocyte-Associated Antigen 4 |
| <b>Da</b>           | Dalton                            |
| <b>DALY</b>         | Disability-Adjusted Life Years    |
| <b>DMBA</b>         | Dimethylbenzanthracene            |
| <b>DMSO</b>         | Dimethyl sulfoxide                |
| <b>DTNB</b>         | Dithiobis-(2-Nitrobenzoic acid)   |
| <b>EA</b>           | Edge Activator                    |
| <b>EE%</b>          | Entrapment Efficiency             |
| <b>EGCG</b>         | Epigallocatechin Gallate          |
| <b>GSH</b>          | Glutathione                       |
| <b>h</b>            | Hour                              |
| <b>H&amp;E</b>      | Hematoxylin and Eosin             |
| <b>HA</b>           | Hyaluronic Acid                   |
| <b>HPV</b>          | Human Papillomavirus              |
| <b>KC</b>           | keratinocytes Carcinomas          |

|                        |   |
|------------------------|---|
| $\lambda_{\text{max}}$ | Lamda maximum- wavelength of maximum absorbance |
| <b>LOD</b>             | Limit of Detection                              |
| <b>LOQ</b>             | Limit of Quantitation                           |
| <b>LPO</b>             | Lipid Peroxidation                              |
| <b>MC1R</b>            | Melanocortin 1 Receptor                         |
| <b>MCC</b>             | Merkel Cell Carcinoma                           |
| <b>MDA</b>             | Malondialdehyde                                 |
| <b>miRNA</b>           | MicroRNAs                                       |
| <b>MSC</b>             | Melanoma Skin Cancer                            |
| <b>mV</b>              | Millivolt                                       |
| <b>NMSC</b>            | Non-melanoma Skin Cancer                        |
| <b>PBS</b>             | Phosphate Buffer Saline                         |
| <b>PC</b>              | Phosphatidylcholine                             |
| <b>PDI</b>             | Polydispersity Indices                          |
| <b>PDT</b>             | Photodynamic Therapy                            |
| <b>PE</b>              | Penetration Enhancers                           |
| <b>PEVs</b>            | Penetration Enhancer-containing Vesicles        |
| <b>PMF</b>             | Polymethoxylated Flavones                       |
| <b>ROS</b>             | Reactive Oxygen Species                         |
| <b>RT</b>              | Radiation Therapy                               |
| <b>SC</b>              | Stratum Corneum                                 |
| <b>SCC</b>             | Squamous Cell Carcinoma                         |
| <b>SOD</b>             | Superoxide Dismutase                            |
| <b>TBA</b>             | Thiobarbituric Acid                             |
| <b>TBARS</b>           | Thiobarbituric Acid Reactive Substance          |